Tiziana Life Sciences (TLSA) CEO buys 667,000 new shares

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd reported that Chief Executive Officer Ivor Elrifi, through a trust, purchased 667,000 shares of common stock on 2026-08-03 at 1.0000 per share in an open-market or private transaction. Following this purchase, his indirectly held stake by trust is 4,472,261 shares.

Insider Trade Summary

Net Buyer: 667,000 shares

Net Buy 1 txn

Insider Elrifi Ivor

Role Chief Executive Officer

Bought 667,000 shs ($667K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	667,000	$1.00	$667K

Holdings After Transaction: COMMON STOCK — 4,472,261 shares (Indirect, By trust)

Key Figures

Shares purchased: 667000.0000 shares Purchase price per share: 1.0000 per share Total shares following transaction: 4472261.0000 shares

3 metrics

Shares purchased 667000.0000 shares COMMON STOCK purchase on 2026-08-03

Purchase price per share 1.0000 per share Price for COMMON STOCK transaction on 2026-08-03

Total shares following transaction 4472261.0000 shares Indirect holdings by trust after purchase

Key Terms

Purchase in open market or private transaction, indirect, By trust

3 terms

Purchase in open market or private transaction financial

"Transaction code description is Purchase in open market or private transaction."

indirect financial

"The ownership_type for the transaction is indirect."

By trust financial

"The nature_of_ownership is described as By trust."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:31 PM Accepted by SEC EDGAR 08/05/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transaction did Tiziana Life Sciences (TLSA) report for its CEO?

Tiziana Life Sciences reported that CEO Ivor Elrifi, via a trust, purchased 667,000 shares of common stock on 2026-08-03. The transaction was reported as an open-market or private purchase and is classified as indirect ownership.

How many TLSA shares did CEO Ivor Elrifi buy and at what price?

CEO Ivor Elrifi bought 667,000 TLSA common shares at a reported price of 1.0000 per share on 2026-08-03. The filing characterizes the move as a purchase in an open market or private transaction held indirectly via a trust.

How many Tiziana Life Sciences (TLSA) shares does the CEO now hold indirectly?

After the reported transaction, CEO Ivor Elrifi’s indirect holdings by trust total 4,472,261 TLSA shares. This figure reflects the position following the 667,000-share purchase disclosed for 2026-08-03 in the Form 4 insider report.

Is the TLSA CEO’s share purchase held directly or through another entity?

The Form 4 shows the CEO’s new shares as held indirectly, with the nature of ownership described as “By trust.” This means the reported 4,472,261 shares after the transaction are owned through a trust rather than in his direct name.

Was the Tiziana Life Sciences (TLSA) CEO trade reported under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating the trade was under a Rule 10b5-1 trading plan. The transaction is instead described simply as a purchase in an open-market or private transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elrifi Ivor

(Last) (First) (Middle)

535 BOYLSTON STREET

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tiziana Life Sciences Ltd [ TLSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	08/03/2026		P		667,000	A	$1	4,472,261	I	By trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ivor Elrifi	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)